Tarriff Scott 13D and 13G filings for Eagle Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-03-18 8:37 pm Sale |
2023-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
Tarriff Scott | 2,470,570 17.600% |
-62,887 (-2.48%) |
Filing |
| 2023-02-14 4:34 pm Purchase |
2022-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
Tarriff Scott | 2,533,457 18.060% |
113,483 (+4.69%) |
Filing |
| 2022-02-14 4:00 pm Purchase |
2021-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
Tarriff Scott | 2,419,974 17.610% |
99,355 (+4.28%) |
Filing |
| 2021-02-16 5:20 pm Purchase |
2020-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX |
Tarriff Scott | 2,320,619 16.660% |
181,403 (+8.48%) |
Filing |